Immunomodulating agents

Other Immunomodulating Agents Plus WR-2721/Thiols. Combining WR-2721 (200 mg/kg ip 30-min preirradiation) and BV (25 mg/kg ip 24-h preirradiation) demonstrates at least additive radioprotection in the ( 54). Protection is optimal when WR-2721 is given 30... 

Lenalidomide is an immunomodulating agent related to thalidomide that was recently approved for the treatment of patients with multiple myeloma and myelodysplastic syndrome (MDS). Lenalidomide lacks the common side effects of thalidomide, such as constipation and peripheral neuropathy. Interim analyses of two phase III trials show that lenalidomide in combination with dexamethasone produces higher response rates than dexamethasone alone in relapsed and refractory myeloma. Adverse effects of lenalidomide include diarrhea, nausea, muscle cramps, hematologic side effects and deep vein thrombosis.42... 

Lacroix, I., Biton, J. and Azerad, R. (1997) Microbial biotransformation of a synthetic immunomodulating agent, HR325. Bioorganic and Medicinal Chemistry, 5, 1369-1380. 

Biologic therapies—primarily immunomodulating agents designed to alter immune responses—comprise first-line systemic therapy. 

Cyclosporine is an immunomodulating agent used mainly to inhibit rejection after transplantations and it has a narrow therapeutic interval. Grapefruit juice is a strong inhibitor of the cyclosporine metabolism (CYP 3A4) and increases the blood concentration of cyclosporine. This can lead to toxicity but can also be used to reduce the doses and decrease the costs of the cyclosporine treatment. 

Cyclo(Arg-Lys) and cyclo(Asp-Lys) were identified as immunomodulation agents. ... 

Immunomodulating agents can both suppress and stimulate various immune functions. This is a heterogenous group of drugs. Increasingly immunostimulants are employed as a form of immunomodulation. Indications for immunostimulant therapy in-... 

It is an immunomodulator agent used locally in the treatment of external genital perianal warts in adults. 

The synthesis of diaryl-thiazolotriazepines 62 from the reaction of l,2,4-triazepine-3-thiones 63 (1.8 mmol) with 2-haloketones 64 (6.25 mmol) in ethanol under reflux for 2h was described <1999T5909> with the goal of creating new immunomodulating agents (Scheme 5). The starting triazepines were prepared by the addition of thiocyanic acid 65 to the chalcones 66 according to an already known method, followed by reaction of the intermediate 67 with hydrazine. 

Immunomodulating agents are being investigated for their potential application in immunodeficiency disorders, chronic infections, and neoplasms. 

---